Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dept. Biomedical and Clinical Sciences "L. Sacco", University of Milan and Pediatric Department, Buzzi Children's Hospital, Milan, Italy.
Acta Diabetol. 2022 Jul;59(7):985-988. doi: 10.1007/s00592-022-01880-5. Epub 2022 Mar 30.
Automated insulin delivery is a game changer for type 1 diabetes treatment.
To describe the benefits of automated insulin delivery in a specific complex setting.
We are herein presenting a case of a patient with type 1 diabetes, in which Hybrid Closed Loop (Medtronic Minimed 670G on Auto Mode) was used over a year during automated peritoneal dialysis. The patient was previously on insulin therapy with sensor augmented pump and we switched him to Hybrid Closed Loop shortly before the begin of dialysis.
Automated insulin delivery produced an increase of time in range (70-180 mg/dl) from 63% to 72%, after 3 months and to 74% after one year. Moreover, no hypoglycemia/hyperglycemia urgencies occurred overall during the year.
The case detailed here is the first report of Hybrid Closed Loop in a patient on automated peritoneal dialysis and it shows an improvement of time in range with a satisfying safety profile in a fragile, aged patient.
自动化胰岛素输送是 1 型糖尿病治疗的重大变革。
描述自动化胰岛素输送在特定复杂环境中的益处。
本文介绍了 1 例 1 型糖尿病患者的病例，该患者在接受自动腹膜透析期间使用了 Hybrid Closed Loop（美敦力 MiniMed 670G 自动模式）超过 1 年。该患者之前使用传感器增强型胰岛素泵进行胰岛素治疗，在开始透析前不久切换到 Hybrid Closed Loop。
经过 3 个月，自动化胰岛素输送使患者的血糖达标时间（70-180mg/dl）从 63%增加到 72%，1 年后增加到 74%。此外，在整个一年中，没有发生低血糖/高血糖紧急情况。
本文详细介绍的病例是 Hybrid Closed Loop 在接受自动腹膜透析的患者中的首例报告，它显示了在一个脆弱、高龄患者中，时间在范围内的改善，并具有令人满意的安全性。
